Germ line mutations associated with breast cancer susceptibility

European Journal of Cancer

Volumn 37, Issue 3, 2001, Pages 300-321

  Iau, P T C ^a   Macmillan, R D ^a   Blamey, R W ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Breast; Cancer; Genes; Genetic; Germ line; Mutations

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; CLINICAL TRIAL; FEMALE; GENE MUTATION; GERM LINE; HUMAN; ONCOGENE; ONCOGENE BRCA2; OVARY CANCER; PENETRANCE; PHENOTYPE; POPULATION RISK; PRIORITY JOURNAL;

EID: 0035123236     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00378-6     Document Type: Review

References (165)

1. Characteristics of familial breast cancer in Sweden: Absence of relation to age and unilateral and bilateral disease
2. Risk factors for breast cancer in women in North Alberta, Canada, as related to age at diagnosis
3. Family history of breast cancer as a risk indicator for the disease
4. Some characteristics of familial breast cancer
5. Genetic study of breast cancer: Identification of a high risk group
6. Breast cancer in families
7. Tumour variation in families with breast cancer
8. Genetic epidemiology of breast cancer: Segregation analysis of 200 Danish pedigrees
9. Inheritance of breast cancer: Evidence of autosomal dominant transmission in high risk families
10. Genetic analysis of breast cancer in the cancer and steroid hormone study
11. Linkage of early-onset breast cancer to chromosome 17q21
12. Familial breast-ovarian cancer locus on chromosome 17q12-23
13. A breast-ovarian cancer susceptibility gene maps to chromosome 17q21
14. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
15. Localisation of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
16. An integrated high-resolution physical map of the DPC/BRCA2 region at chromosome 13q12
17. Identification of the breast cancer susceptibility gene BRCA2
18. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families
19. Genetic heterogeneity of breast-ovarian cancer revisited
20. Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families
21. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
22. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence
23. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population case-control studies of ovarian cancer
24. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
25. Breast and ovarian cancer incidence in BRCA1-mutation carriers
26. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
27. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients
28. Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer
29. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2
30. Novel inherited mutations and variable expressibility of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families
31. BRCA1 and BRCA2 testing: Weighing the demand against the benefits
32. BRCA1 and BRCA2: Penetrating the clinical arena
33. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
34. The rapid detection of unknown mutations in nucleic acids
35. Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer
36. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms
37. Rapid detection of BRCA1 mutations by the protein truncation test
38. Strand-seperating conformational polymorphism analysis: Efficacy of detection of point mutations in the human ornithine delta-aminotransferase gene
39. Detecting single base substitutions as heteroduplex polymorphisms
40. Protein truncation test (PTT) for rapid detection of translation-terminating mutations
41. Collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene
42. Mutations of the APC (adenomatous polyposis coli) gene
43. Molecular diagnosis of familial adenomatous polyposis
44. Common origin of the BRCA1 mutations in Canadian breast and ovarian cancer families
45. Recurrent germ line BRCA1 mutations in extended African American families with early-onset breast cancer
46. Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites
47. BRCA1 sequence analysis in women at high risk for susceptibility mutations
48. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17
49. BRCA1 genomic deletions are major founder effects in Dutch breast cancer patients
50. The complete BRCA2 gene and mutation in chromosome 13q-linked kindreds
51. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk
52. Frequently occurring germ line mutation of the BRCA1 gene in ovarian cancer families from Russia
53. Germline mutation of BRCA1 in Japanese breast cancer families
54. Recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families
55. BRCA1 germ line mutational spectrum in Italian families from Tuscany: A high frequency of novel mutations
56. Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by the protein truncation test
57. Study of a single BRCA2 mutation with high carrier frequency in a small population
58. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes
59. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals
60. Mutation analysis of the BRCA1 gene in ovarian cancer
61. BRCA1 mutation in Ashkenazi Jewish women
62. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: A genetic study of 15 185delAG mutation kindreds
63. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected with breast cancer
64. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jews is approximately 1 percent
65. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
66. BRCA1- related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics
67. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history
68. A common BRCA1 mutation in Norwegian breast and ovarian cancer families Am?
69. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing
70. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer
71. Evidence of a founder BRCA1 mutation in Scotland
72. Risks of cancer in BRCA1-mutation carriers
73. Colorectal cancer in hereditary breast cancer kindreds
74. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germ line mutation carriers
75. Germline BRCA1 mutations in selected men with prostate cancer
76. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer
77. Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer
78. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families
79. Cancer risk in BRCA2 mutation carriers
80. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia
81. Germline BRCA2 gene mutations in patients in apparently sporadic pancreatic carcinomas
82. Familial pancreatic cancer
83. Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1 and BRCA2 mutations
84. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men
85. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer
86. BRCA1 and BRCA2 have a limited role in familial prostate cancer
87. Confirmation of BRCA1 by analysis of germ line mutations linked to breast and ovarian cancer in ten families
88. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: Evidence for additional susceptibility genes
89. Germline mutations of BRCA1 gene in breast and ovarian cancers provide evidence for a genotype-phenotype correlation
90. A high incidence of BRCA1 mutations in breast-ovarian cancer families
91. Variation of risks of breast and ovarian cancer associated with different germ line mutations of the BRCA2 gene
92. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: Results of an international study
93. BRCA1 mutations in primary breast and ovarian carcinomas
94. BRCA2 mutations in primary breast and ovarian cancers
95. Histoprognostic grade in BRCA1-associated breast cancer
96. Hereditary breast cancer: Pathology, prognosis and BRCA1 and BRCA2 gene linkage
97. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer
98. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
99. The histological phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germ line mutations
100. Pathology of familial breast cancer: Differences between breast cancer in carriers of BRCA1 and BRCA2 and sporadic cases
101. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
102. Are medullary and atypical medullary cancers an indication for BRCA1 mutation screening
103. Intraductal component and BRCA1-associated breast cancer
104. In-situ breast cancer and BRCA1
105. BRCA2 hereditary breast cancer pathophenotype
106. Inherited BRCA2 mutaion associated with high grade breast cancer
107. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
108. Tumour biological features of BRCA1-induced breast and ovarian cancer
109. Survival and tumour characteristics of breast cancer patients with germ line mutations of BRCA1
110. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers
111. Novel indications for BRCA1 screening using individual clinical and morphological features
112. Survival in hereditary breast cancer associated with germ line mutations of BRCA2
113. Clinicopathologic analysis of BRCA1 or BRCA2 associated hereditary breast carcinoma in Japanese women
114. Breast cancer survival in BRCA1 carriers
115. Breast cancer incidence, penetrance and survival in probably carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21
116. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden
117. Prognosis of BRCA1 hereditary breast cancer
118. P53 protein expression in human breast carcinoma: Relationship to expression of epidermal growth factor, c-erbB-2 protein overexpression and oestrogen receptor
119. Breast carcinomas arising from carriers of mutations in BRCA1 and BRCA2: Are they prognostically different?
120. The influence of familial and hereditary factors on the prognosis of breast cancer
121. Survival of patients with breast cancer and BRCA1 mutations
122. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
123. Survival in early onset breast cancer patients
124. BRCA-associated breast cancer in young women
125. The incidence and gene frequency of ataxia-telangiectasia on the United States
126. Breast and other cancers in families with ataxia-telangiectasia
127. Breast cancer and other cancers in Nowegian families with ataxia-telangiectasia
128. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain
129. Cancer risks in AT heterozygotes
130. The inherited component of cancer
131. Genetic haplotyping of ataxia-telangiectasia families localises the major gene to an 850 kb region on chromosome 11q23.1
132. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase
133. Molecular genotyping shows that at heterozygotes are predisposed to breast cancer
134. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia
135. ATM mutations and phenotypes in ataxia-telangiectasia famlies in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer
136. Breast cancer in ataxia-telangiectasia (AT) heterozygotes: Haplotype study in French AT families
137. Heterozygous ATM mutations do not contribute to early onset of breast cancer
138. The ATM gene and susceptibility to breast cancer: Analysis of 38 breast tumours reveals no evidence of mutation
139. ATM mutations in cancer families
140. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene
141. ATM-heterozyhous germ line mutations contribute to breast cancer-susceptibility
142. AT-tributable risks?
143. Soft tissue sarcomas, breast cancer and other neoplasms: A familial syndrome?
144. Prospective study of a family cancer syndrome
145. Cancer in survivors of childhood soft tissue sarcoma and their relatives
146. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms
147. Inherited p53 mutations in breast cancer
148. P53 mutations in breast cancer
149. Heterozygoues germ line hCHK2 mutations in Li-Fraumeni Syndrome
150. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
151. Cowden's disease: A possible new symptom complex with multiple system involvement
152. Multiple hamartoma syndrome (Cowden's disease)
153. Gastrointestinal polyposis with orocutaneous harmatomas (Cowden's disease)
154. Cowden's disease (multiple harmatoma and neoplasia syndrome)
155. Cowden's disease: A cutaneous marker of breast cancer
156. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
157. TEP1, encoded by a candidate tumour suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β
158. Mutations at pTEN in patients with Bannayan-Riley-Ruvalcaba phenotype
159. Analysis of the 10q23 chromosomal region and the pTEN gene in human sporadic breast carcinoma
160. Frequent inactivation of pTEN/MMAC1 in primary prostatic cancer
161. PTEN/MMAC1 mutations in endometrial cancers
162. Disruption of the MMAC1/pTEN gene by deletion or mutation is a frequent event in malignant melanoma
163. Novel germ line mutations in the pTEN tumour suppressor gene found in women with multiple cancers
164. Bloom syndrome: A Mendellian prototype of somatic mutational disease
165. A genome-wide map showing common regions of loss of heterozygosity (LOH)/allelic imbalance in breast cancer